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EDITORIAL

SUPPLEMENT ARTICLE

On a Multinational Assessment of Rotavirus Disease
in Europe
David O. Matson
Graduate Program in Public Health, Eastern Virginia Medical School and Old Dominion University, Norfolk

Rotaviruses were discovered in the 1960s
in animals and in the 1970s in humans;
the latter discovery was made by an intrepid group who performed duodenal biopsies on children with acute gastroenteritis (AGE) [1]. By the late 1970s, data
already clearly indicated that rotavirus was
the cause of the annual winter peak of
AGE affecting young children, as well as
a frequent cause of severe gastroenteritis
in various animal species (e.g., [2–5]). Use
of the retrospectroscope clarified or left as
tantalizing the suggestion that rotaviruses
were the cause of the annual “winter vomiting syndrome” first described in children
in 1910 in Japan [6] and in 1929 in the
United States [7]. The recognition of that
winter peak was a result of improved water
and sewage handling that markedly reduced exposure to bacterial and parasitic
pathogens but not to the common viral
pathogens.
Many studies have been conducted to
examine the burden of rotavirus disease.
Most of these have been cross-sectional in
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design, have documented the high (usually 30%–60%) frequency of rotavirus detection among children hospitalized with
AGE, and have found that the more intense the severity of illness, the more frequently rotavirus is detected. Longitudinal, cohort studies of rotavirus disease
have been fewer in number, and most of
these have suffered from study design issues, such as enrollment of subjects at an
age later than birth, resulting in infections
at an early age being missed, or assessment
of rotavirus infection only by detection of
virus excreted in stool, when a large fraction of rotavirus infections are detected
not by routinely applied assays but by seroresponse. Population-based studies have
been even less frequently undertaken, and
most such studies have depended on indirect measures of rotavirus disease—
namely, the assignment of International
Classification of Diseases codes, along with
occurrence of the codes within age, season,
and list position (within a list of assigned
International Classification of Diseases
codes) distributions [8].
Direct, active surveillance always is preferred to indirect measures in attempts to
identify cases of any disease. In the studies
reported in this supplement to the Journal
of Infectious Diseases, conducted by Pierre
Van Damme and his colleagues in Europe
[9–12], several laudable features were part
of the study design: establishment of defined geographic surveillance regions with
known populations, active surveillance at
treatment sites for different acuities of

AGE and for that fraction of cases caused
by rotavirus, application of the same study
protocol within different countries at the
same time, and broad probing for factors
affecting the cost of the illness and care
for it.
Perhaps the authors expected that the
cumulative results of this effort would lead
to data enabling a unified, simplified extrapolation, to Europe or to western Europe, of the burden of the syndrome and
that fraction caused by rotavirus. The surprise, for me, is the variance that was observed in the results: multifold differences
among study regions in the incidence of
AGE of all causes in the same age group,
similar differences among regions in the
incidence of AGE attributable to rotavirus,
major differences in the prevalence of different rotavirus serotypes in study regions
not too far apart, and striking differences
in estimates of the cost of AGE as a syndrome and of AGE attributable to rotavirus. The least unexpected of these results
are the differences in rotavirus serotype
prevalence by region. We have known from
prior studies that rotavirus serotype distribution changes every 1–2 years in some
regions, but a single serotype also may be
predominant for as many as 10 years in a
region.
These differences in disease incidence
were, perhaps, not unexpected, because we
still have major differences within countries with well-developed infrastructure in
water and sewage handling and in living
conditions that affect exposure to enteric
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pathogens. Particular differences that affect gastroenteritis disease burden include
the presence and amount of sewage handling through septic tanks, practices for
the pretreatment of sewage before discharge, types and degree of contamination
of drinking source waters (lakes and rivers in comparison with aquifers accessed
through deep or shallow wells and the soil
and rock formations above them), differences in close exposures to animals that
can be a source of human infections, and
the degree of crowding in living conditions. For the latter, think only of differences in the “environmental quality”
among and within child care centers, nursing homes, and hospitals: food handlers
who do not wash their hands or wear
mandated gloves; changing of soiled diapers and bed clothes and their disposal
and cleaning at inappropriate locations,
such as in kitchens; and the use of contaminated water for the washing of food.
It also is possible that, just as physicians
differ in the frequency of referral of patients from the office setting to the emergency department and/or hospital setting,
parents are also likely to differ in their
sense of a need for medical care for their
child’s gastroenteritis episode. There are
hints that the study populations may have
differed to large degrees; for example, the
rate of parents speaking a language not
native to the study region was 41% at one
study site, whereas this rate was much
lower (!10%) elsewhere.
The limitations of the studies perhaps
are overemphasized by the authors. It is
important to emphasize the positive aspects: large, predefined study populations;
active surveillance at treatment sites intended to care for differing acuities of disease; and uniform definitions and analysis factors. The authors properly restate,
on the basis of their work, that rotavirus
is a significant cause of an expensive potentially vaccine-preventable disease in
Europe. Their results provide useful information needed to design surveillance
protocols for assessing vaccine effective-

ness. It is worth noting that Europe now
has 2 licensed rotavirus vaccines and that
these 2 vaccines differ greatly in their approaches to the induction of protective
immunity. One vaccine is monovalent, the
other pentavalent. Although phase 3 studies [13, 14] have given similar overall efficacy results, differences were found in
serotype-specific efficacy that would be expected from the differences in antigenic
composition of the vaccines. The 2 vaccines also differ in the number of studied
doses. I encourage the authors, in a followup report, to consider the fraction of vaccine-preventable disease by study region
and to study the efficacy of the 2 licensed
vaccines. It will be important, going forward, to continue to measure accurately
the differences in effectiveness related to
the number of vaccine doses and serotypespecific protection. In this regard, the variability in observed rates of illness, patterns
of treatment related to physician referral
practices, and serotype distribution in
these studies with a common, robust study
protocol suggest that ongoing surveillance
will need careful design. Active surveillance is also likely to trump indirect surveillance in this undertaking.
The observation of significant differences among age distributions of prevailing serotypes in the different study regions
deserves some comment. When examined
over multiple years and/or over different
regions, rotavirus serotypes do not show
significant differences in age distribution
among affected children; such findings
have falsely led to the conclusion that rotavirus serotypes never differ in age distribution. What should we think when
faced with the REVEAL Study findings of
marked differences in serotype distribution by age? Distributions of rotavirus serotypes do differ within a single region,
across ages from one season to the next,
and among widely separated regions in the
same rotavirus season [15, 16]. The patterns observed result from the introduction of serotypes that are new to a region;
these serotypes first appear within cities
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and then spread over a 2- to 3-year period
to the surrounding rural regions. Spread
of the new serotype across broad geographic regions may take years, unlike influenza and more like cholera [17, 18].
When the epidemic serotype enters a population, its age distribution is broader than
that of established, endemic serotypes, affecting a greater percentage of young infants whose mothers lack recent exposure
to the serotypes and of older children and
adults whose acquired immunity is insufficient to protect against illness caused by
the epidemic type. These patterns have
important implications for the design of
appropriate disease and serotype surveillance after the introduction of mass
immunization.
We can look forward to a reduced burden of rotavirus disease, now that we have
new vaccines to prevent infection and illness. The success of that intervention
strategy will be measured by the collection
of accurate data. Van Damme and colleagues have provided a model from the
prelicensure period for how to consider
such studies now that mass vaccination
has begun.
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